SYNTHETIC BIOLOGY STRATEGIES FOR DRUG DISCOVERY

The landscape of pharmaceutical research is undergoing a fundamental shift driven by the integration of synthetic biology (SB). Rather than relying solely on traditional chemical synthesis or the direct extraction of natural products, this discipline treats biological systems as programmable entities. By applying rigorous engineering principles to modify organisms, researchers can now design specific therapeutic outcomes and overcome long-standing barriers in drug development. This approach is currently transforming every phase of the lifecycle-from the identification of novel targets and the validation of disease models to the large-scale manufacturing of complex molecules through metabolic engineering and CRISPR-Cas9 technologies. Furthermore, SB facilitates the exploration of chemical diversity via late-stage functionalization and the biosynthesis of natural product analogs in genetically tractable hosts. This review explores the systematic application of SB to improve the speed, cost-efficiency, and quality of drug discovery, highlighting its potential to revitalize the pharmaceutical industry’s focus on complex biological scaffolds and personalized medicine.